Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03039114
Title Study Evaluating Safety and Efficacy of INCB050465 Combined With Bendamustine and Obinutuzumab in Relapsed or Refractory Follicular Lymphoma (CITADEL-102)
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Incyte Corporation

follicular lymphoma


Bendamustine + Obinutuzumab + Parsaclisib

Age Groups: senior | adult
Covered Countries USA | ITA | ESP

No variant requirements are available.